Experimental combo therapy targets aggressive leukemia complication
NCT ID NCT04679012
Summary
This study is testing whether adding a newer targeted drug called polatuzumab vedotin to a standard chemotherapy combination works better for people with Richter's transformation. Richter's transformation is when a slower-growing blood cancer (chronic lymphocytic leukemia) suddenly turns into a much more aggressive lymphoma. The trial will enroll about 20 adults who haven't had prior treatment for this aggressive phase, and will check if the new combination can put the disease into remission and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact
-
Mount Sinai- Icahn School of Medicine
RECRUITINGNew York, New York, 10029, United States
Contact
Contact
-
Ohio state University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.